NetScientific PLC (LON:NSCI) has noted that its portfolio company, Vortex BioSciences Inc, has announced a promising report published by Nature Scientific Reports.
The AIM-listed transatlantic healthcare IP commercialisation group said the peer reviewed report, titled "Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer" describes the use of Vortex's technology.
READ: NetScientific hails progress of its portfolio companies in 2017
It added that the technology was used to capture circulating tumour cells (CTCs), in combination with the use of a novel immunofluorescence assay, for measuring programmed cell death ligand 1 (PD-L1) expression on the surface of the CTCs from patients with metastatic non-small cell lung cancer (NSCLC).
Commenting on the news, Francois Martelet, CEO of NetScientific and chairman of Vortex BioSciences said: "This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients.
"Recent clinical trials of PD-1 and PD-L1 inhibitors have returned promising clinical responses, providing a rationale for use of the VTX 1 system in personalised medicine."